Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients. - Wikidata - awgldk - TriplyDB

Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

http://www.wikidata.org/entity/Q33935930

about

Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network.Role of raltegravir in HIV-1 management.

P2860

Q36311771-8ABE909B-3FEC-4D6B-8C8D-1CB25B6020FF Q36702759-9731A619-8B99-4E8C-98BF-841E09313D64 Q38002011-7F91AAFA-6D95-4E77-89C1-CEA669933742

P2860

Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

http://www.wikidata.org/entity/Q33935930

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Similar efficacy of raltegravi ...... reatment-experienced patients.

@ast

Similar efficacy of raltegravi ...... reatment-experienced patients.

@en

type

label

Similar efficacy of raltegravi ...... reatment-experienced patients.

@ast

Similar efficacy of raltegravi ...... reatment-experienced patients.

@en

prefLabel

Similar efficacy of raltegravi ...... reatment-experienced patients.

@ast

Similar efficacy of raltegravi ...... reatment-experienced patients.

@en

P1433

Q33935930-5F625BA5-05B7-45E5-BB3A-6BFFBD873847

P1476

Q33935930-544E0FA4-0BC8-46C2-81C7-2F4E595DC176

P2093

Q33935930-3206F14F-DB79-4309-892F-36C3C5BD4284

Q33935930-4019292B-B199-43CD-AD07-39A897AA089C

Q33935930-5B4E9F8C-E15D-490D-BA4F-9F847C6FBB0E

Q33935930-5EE7D614-FF04-420E-B9BE-F39D3288E846

Q33935930-60AA91F2-1875-44A8-AABD-551C54BCB126

Q33935930-63888F00-9A6C-432D-9096-6FA580EC03E2

Q33935930-697B6AB9-CF40-435A-8378-3A73325AB671

Q33935930-7630558D-979F-4C71-91A1-14D8B93859BD

Q33935930-80F26583-8901-4471-9960-9B465DE786B0

Q33935930-92C8C570-2195-4F4B-A8ED-DA2141FD99D1

P2860

Q33935930-1338CA63-67D7-4EFB-B0E7-99B77E62E722

Q33935930-39E322D2-E9BD-40BB-96D2-BBE613591FC6

Q33935930-541930B1-C702-4D4E-B3B3-87B0F23DF1B5

Q33935930-6EB54834-B928-4C9D-9504-77479C85FAF3

Q33935930-81A3D57E-5196-4B02-8904-C6AD2C8ED61C

Q33935930-97B53C35-21DF-4CC0-9C7C-71AC3D5B925E

Q33935930-99C1B79A-1037-4716-BFB2-8F2CBA62E462

Q33935930-CEC11782-8E55-447B-9223-8BDE47EE145F

Q33935930-DCE1AE26-F31F-4D4E-91CA-737520023AAE

Q33935930-F08A9B02-85BA-4D69-AF1C-74F859A14BC0

P304

Q33935930-B5903318-9169-47C6-AED9-E6E173BD1FA0

P31

Q33935930-90AB1EF5-E413-4D1A-979D-D7DE62119361

P356

Q33935930-16AEFB5E-93D7-4712-AFD5-5763401C73E5

P433

Q33935930-05212B47-AA5B-422D-B506-09F98189D96F

P478

Q33935930-DB7FF1FF-1D94-4ACC-9FCD-3E635E0CD6BA

P577

Q33935930-E4CC87FA-47B8-468B-99D0-B166FBFF166E

P698

Q33935930-E166669B-CF18-4D90-BD65-38DAEA2E2BCE

P356

P1433

HIV Clinical Trials

P1476

Similar efficacy of raltegravi ...... reatment-experienced patients.

@en

P2093

Amy Colson

http://www.w3.org/2001/XMLSchema#string

Anne Habel

http://www.w3.org/2001/XMLSchema#string

Bruce Rashbaum

http://www.w3.org/2001/XMLSchema#string

Calvin Cohen

http://www.w3.org/2001/XMLSchema#string

Chiu-Bin Hsiao

http://www.w3.org/2001/XMLSchema#string

Daniel J Skiest

http://www.w3.org/2001/XMLSchema#string

David Barker

http://www.w3.org/2001/XMLSchema#string

Douglas Ward

http://www.w3.org/2001/XMLSchema#string

Edwin Dejesus

http://www.w3.org/2001/XMLSchema#string

Frances Santiago

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir: the first HIV type 1 integrase inhibitor

Raltegravir with optimized background therapy for resistant HIV-1 infection

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.

P304

131-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HCT1203-131

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21684853

http://www.w3.org/2001/XMLSchema#string